• Ana-COVID study
• Anakinra for COVID-19 hyperinflammatory state • Prospective/retrospective cohort study
• Hospitalized adults with critical lung function
• Cohort with CVD (hypertension, stroke, cardiopathy)
• Primary outcome of ICU admission with mechanical ventilation or death
•  N = 52 anakinra + standard care
•  N = 44 standard care • Anakinra 100 mg s.c. twice daily for 3 days
• Then anakinra 100 mg s.c. once daily for 7 days • Significantly reduced need for mechanical ventilation or death HR 0.22 (0.11–0.41) • Anakinra may be associated with improved outcomes in patients with severe COVID-19 infection, including those with CVD and history of cardiovascular events
• May be due to mitigation of inflammatory cascade (Huet et al., 2020)